STOCK TITAN

Esperion Therapeutics (ESPR) Stock News, Jan-Mar 2026

ESPR

Esperion Therapeutics develops and commercializes therapies for cardiometabolic and rare/orphan diseases, with a commercial focus on oral, once-daily, non-statin LDL-C treatments for patients at risk for cardiovascular disease. Company news commonly covers NEXLETOL bempedoic acid data, CLEAR Outcomes analyses, dyslipidemia guideline developments, financial results, business updates, and material agreements.

Esperion's news also reflects portfolio expansion through its completed acquisition of Corstasis Therapeutics and Enbumyst bumetanide nasal spray, an FDA-approved loop diuretic for edema associated with congestive heart failure and hepatic or renal disease in adults. Additional recurring topics include ACLY biology, product commercialization, pipeline work in Primary Sclerosing Cholangitis and renal diseases, and governance or capital-structure matters.

Rhea-AI Summary

Esperion (NASDAQ: ESPR) presented two post-hoc CLEAR Outcomes analyses at ACC.26 (Mar 28-30, 2026) showing clinical benefits of bempedoic acid (NEXLETOL/NEXLIZET). Key findings: a 22% reduced risk of ischemic stroke in statin-intolerant patients and similar MACE risk reduction in patients with autoimmune or inflammatory diseases.

The company highlighted safety considerations including hyperuricemia, gout risk, and a small increased tendon rupture incidence observed in trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
none
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced two moderated poster presentations from the CLEAR Outcomes trial at the American College of Cardiology 2026 Annual Scientific Session (ACC.26), March 28-30 in New Orleans.

Both analyses evaluate bempedoic acid in underrepresented populations: stroke incidence in statin-intolerant patients and cardiovascular outcomes in patients with autoimmune or inflammatory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced that bempedoic acid earned multiple Class 1 recommendations in the 2026 ACC/AHA multisociety dyslipidemia guideline (published March 16, 2026), including for patients with statin intolerance, severe hypercholesterolemia, and selected primary and secondary prevention groups.

The guideline places bempedoic acid alongside ezetimibe and PCSK9 mAb after statins, reintroduces LDL-C targets, and supports earlier combination oral therapy to reduce ASCVD risk.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.25%
Tags
none
Rhea-AI Summary

Esperion (NASDAQ: ESPR) reported FY2025 total revenue of $403.1M (21% Y/Y) and Q4 revenue of $168.4M (144% Y/Y). U.S. net product revenue grew ~38% Y/Y to $159.6M for FY2025. The company announced an agreement to acquire Corstasis and Enbumyst™, and strengthened patent settlements and payer coverage.

Key financials: Q4 U.S. product sales $43.7M, collaboration revenue driven by a $90M Otsuka payment, FY net loss $22.7M, cash $167.9M, and 2026 operating expense guidance of $225M–$255M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) agreed to acquire Corstasis to add Enbumyst™ (bumetanide nasal spray), the first FDA‑approved intranasal loop diuretic (approved Sept 2025), for edema associated with CHF, hepatic and renal disease. The deal includes a $75 million upfront cash payment, up to $180 million in milestones, low double‑digit royalties, and expected close in Q2 2026.

Esperion will finance the transaction via existing credit facilities and royalty monetization and expects the product to leverage its cardiovascular commercial infrastructure to drive double‑digit revenue growth and expand its portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.01%
Tags
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) will report Q4 and full-year 2025 financial results before the market opens on Tuesday, March 10, 2026. Management will host a live audio webcast at 8:00 a.m. ET to discuss results and business updates.

Webcast access and a replay will be available on the company's investor site, with the replay archived for approximately 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.20%
Tags
earnings date
Rhea-AI Summary

Esperion (NASDAQ: ESPR) will participate in the 2026 Citizens Life Sciences Conference on March 11, 2026, presenting at 8:25 a.m. ET. The presentation will be webcast live and accessible via the company’s investor and media website. A replay will be available about two hours after the call and archived for approximately 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced a settlement with Alkem Laboratories resolving patent litigation over NEXLETOL and NEXLIZET. Under the agreement, Alkem agreed not to market generic versions in the U.S. prior to April 19, 2040, subject to customary limited exceptions.

Litigation against four other ANDA filers remains pending, and there is no assurance those cases will prevent earlier generic entry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.50%
Tags
none
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced on February 10, 2026 the grant of 40,200 restricted stock units (RSUs) to 11 newly hired employees under its 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).

The RSUs vest 25% at one year, with the remaining 75% vesting in twelve equal quarterly installments, subject to continued employment and plan terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
Rhea-AI Summary

Esperion (NASDAQ: ESPR) provided preliminary full‑year 2025 results and a business update on Jan 11, 2026, and outlined its long‑term Vision 2040 growth strategy. Key preliminary figures: U.S. net product sales $156–$160M (+35%–38% vs 2024), total revenue $400–$408M (+20%–23% vs 2024; ~55%–59% excl. one‑time milestones), and cash & cash equivalents ≈ $168M at year‑end 2025. Q4 retail prescription equivalents rose 34% Y/Y and 11.3% Q/Q. Company expects 2026 operating expenses $210–$245M and announced R&D and global commercial expansion, including IND‑enabling work for ESP‑2001 (PSC) and plans for oral triple combination lipid therapies targeted for commercialization in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
none

FAQ

What is the current stock price of Esperion Therapeutics (ESPR)?

Esperion Therapeutics (ESPR) last closed at $3.18.